Image of Serum Levels of FGF21 and Prediction of Cardiovascular Events

LITERATURE

Serum Levels of FGF21 and Prediction of Cardiovascular Events


Over the last decade, the discovery of endocrine fibroblast growth factors (eFGFs) and their signaling pathways with regulatory functions in cell metabolism, but not proliferation, is among the major breakthroughs in the field of endocrinology and metabolism [1, 2]. Among eFGFs, FGF21 has attracted much attention as a potential pharmacotherapy against major metabolic diseases, such as obesity, diabetes, fatty liver disease, cardiometabolic diseases, and collateral tissue damage, as demonstrated in both animal models and human clinical patients [3–5].


Availability

REQJ544-03Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Cardiology 2018;139:219–221
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous